S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)

Exelixis (EXEL) Competitors

$19.20
-0.15 (-0.78%)
(As of 06/9/2023 ET)
Compare
Today's Range
$19.18
$19.43
50-Day Range
$18.17
$20.48
52-Week Range
$14.87
$22.47
Volume
4.55 million shs
Average Volume
2.91 million shs
Market Capitalization
$6.25 billion
P/E Ratio
40.00
Dividend Yield
N/A
Price Target
$25.33

EXEL vs. HALO, NBIX, RGEN, BCRX, CRSP, PCVX, DNLI, ABCM, DNA, and VIR

Should you be buying Exelixis stock or one of its competitors? The main competitors of Exelixis include Halozyme Therapeutics (HALO), Neurocrine Biosciences (NBIX), Repligen (RGEN), BioCryst Pharmaceuticals (BCRX), CRISPR Therapeutics (CRSP), Vaxcyte (PCVX), Denali Therapeutics (DNLI), Abcam (ABCM), Ginkgo Bioworks (DNA), and Vir Biotechnology (VIR). These companies are all part of the "biological products, except diagnostic" industry.

Exelixis vs.

Halozyme Therapeutics (NASDAQ:HALO) and Exelixis (NASDAQ:EXEL) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking, profitability, risk and earnings.

In the previous week, Exelixis had 2 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 6 mentions for Exelixis and 4 mentions for Halozyme Therapeutics. Exelixis' average media sentiment score of 1.01 beat Halozyme Therapeutics' score of 0.34 indicating that Exelixis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Halozyme Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Exelixis
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Exelixis received 75 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. However, 68.99% of users gave Halozyme Therapeutics an outperform vote while only 68.62% of users gave Exelixis an outperform vote.

CompanyUnderperformOutperform
Halozyme TherapeuticsOutperform Votes
476
68.99%
Underperform Votes
214
31.01%
ExelixisOutperform Votes
551
68.62%
Underperform Votes
252
31.38%

Halozyme Therapeutics has higher earnings, but lower revenue than Exelixis. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme Therapeutics$660.12 million6.76$202.13 million$1.3125.88
Exelixis$1.61 billion3.88$182.28 million$0.4840.00

Halozyme Therapeutics has a net margin of 25.76% compared to Exelixis' net margin of 9.24%. Halozyme Therapeutics' return on equity of 184.32% beat Exelixis' return on equity.

Company Net Margins Return on Equity Return on Assets
Halozyme Therapeutics 25.76% 184.32% 16.05%
Exelixis 9.24% 6.20% 5.10%

Halozyme Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

96.3% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 84.7% of Exelixis shares are owned by institutional investors. 2.4% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 2.9% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Halozyme Therapeutics presently has a consensus price target of $54.78, suggesting a potential upside of 60.97%. Exelixis has a consensus price target of $25.33, suggesting a potential upside of 31.67%. Given Halozyme Therapeutics' higher probable upside, research analysts clearly believe Halozyme Therapeutics is more favorable than Exelixis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.78
Exelixis
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.88

Summary

Halozyme Therapeutics beats Exelixis on 10 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EXEL vs. The Competition

MetricExelixisBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$6.25B$2.59B$4.57B$6.28B
Dividend YieldN/A2.34%2.37%6.18%
P/E Ratio40.003.2699.4112.40
Price / Sales3.88181.323,298.1388.51
Price / Cash30.7416.3291.54113.53
Price / Book2.503.484.685.29
Net Income$182.28M$53.42M$118.02M$193.02M
7 Day Performance0.05%1.18%0.92%1.55%
1 Month Performance-0.16%5.57%1.50%5.18%
1 Year Performance1.69%10.42%8.31%3.05%

Exelixis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HALO
Halozyme Therapeutics
3.2198 of 5 stars
$33.98
+2.8%
$54.78
+61.2%
-26.1%$4.47B$660.12M25.94145
NBIX
Neurocrine Biosciences
2.6617 of 5 stars
$95.41
+1.7%
$125.21
+31.2%
-3.9%$9.31B$1.60B159.021,200Analyst Report
RGEN
Repligen
2.8184 of 5 stars
$168.72
+2.3%
$208.56
+23.6%
-1.7%$9.39B$801.54M57.192,025
BCRX
BioCryst Pharmaceuticals
1.9616 of 5 stars
$8.53
+2.0%
$15.00
+75.8%
-19.0%$1.61B$270.83M-7.05358
CRSP
CRISPR Therapeutics
2.136 of 5 stars
$64.58
+2.4%
$75.05
+16.2%
-15.2%$5.10B$1.20M-9.61473Analyst Upgrade
News Coverage
Gap Up
PCVX
Vaxcyte
1.9154 of 5 stars
$51.89
+1.9%
$65.00
+25.3%
+146.5%$4.86BN/A-15.0089Positive News
DNLI
Denali Therapeutics
2.0701 of 5 stars
$30.58
+0.4%
$52.09
+70.3%
+25.2%$4.19B$108.46M-10.66380
ABCM
Abcam
2.3894 of 5 stars
$17.20
+1.5%
$23.00
+33.7%
+5.6%$3.94B$447.49M0.001,760News Coverage
Positive News
High Trading Volume
DNA
Ginkgo Bioworks
1.9013 of 5 stars
$1.84
+11.6%
$4.10
+123.4%
-50.8%$3.83B$477.71M-1.781,292Options Volume
Gap Up
VIR
Vir Biotechnology
1.8105 of 5 stars
$26.04
-2.4%
$49.75
+91.1%
+3.5%$3.49B$1.62B-23.67444Insider Selling

Related Companies and Tools

This page (NASDAQ:EXEL) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -